211 related articles for article (PubMed ID: 24900443)
1. Discovery of GNF-5837, a Selective TRK Inhibitor with Efficacy in Rodent Cancer Tumor Models.
Albaugh P; Fan Y; Mi Y; Sun F; Adrian F; Li N; Jia Y; Sarkisova Y; Kreusch A; Hood T; Lu M; Liu G; Huang S; Liu Z; Loren J; Tuntland T; Karanewsky DS; Seidel HM; Molteni V
ACS Med Chem Lett; 2012 Feb; 3(2):140-5. PubMed ID: 24900443
[TBL] [Abstract][Full Text] [Related]
2. (R)-2-Phenylpyrrolidine Substituted Imidazopyridazines: A New Class of Potent and Selective Pan-TRK Inhibitors.
Choi HS; Rucker PV; Wang Z; Fan Y; Albaugh P; Chopiuk G; Gessier F; Sun F; Adrian F; Liu G; Hood T; Li N; Jia Y; Che J; McCormack S; Li A; Li J; Steffy A; Culazzo A; Tompkins C; Phung V; Kreusch A; Lu M; Hu B; Chaudhary A; Prashad M; Tuntland T; Liu B; Harris J; Seidel HM; Loren J; Molteni V
ACS Med Chem Lett; 2015 May; 6(5):562-7. PubMed ID: 26005534
[TBL] [Abstract][Full Text] [Related]
3. Tropomyosin receptor kinase: a novel target in screened neuroendocrine tumors.
Aristizabal Prada ET; Heinzle V; Knösel T; Nölting S; Spöttl G; Maurer J; Spitzweg C; Angele M; Schmidt N; Beuschlein F; Stalla GK; Blaser R; Kuhn KA; Auernhammer CJ
Endocr Relat Cancer; 2018 May; 25(5):547-560. PubMed ID: 29563190
[TBL] [Abstract][Full Text] [Related]
4. TrkB inhibition by GNF-4256 slows growth and enhances chemotherapeutic efficacy in neuroblastoma xenografts.
Croucher JL; Iyer R; Li N; Molteni V; Loren J; Gordon WP; Tuntland T; Liu B; Brodeur GM
Cancer Chemother Pharmacol; 2015 Jan; 75(1):131-41. PubMed ID: 25394774
[TBL] [Abstract][Full Text] [Related]
5. Identification and preclinical characterization of AZ-23, a novel, selective, and orally bioavailable inhibitor of the Trk kinase pathway.
Thress K; Macintyre T; Wang H; Whitston D; Liu ZY; Hoffmann E; Wang T; Brown JL; Webster K; Omer C; Zage PE; Zeng L; Zweidler-McKay PA
Mol Cancer Ther; 2009 Jul; 8(7):1818-27. PubMed ID: 19509272
[TBL] [Abstract][Full Text] [Related]
6. Discovery of CH7057288 as an Orally Bioavailable, Selective, and Potent pan-TRK Inhibitor.
Ito T; Kinoshita K; Tomizawa M; Shinohara S; Nishii H; Matsushita M; Hattori K; Kohchi Y; Kohchi M; Hayase T; Watanabe F; Hasegawa K; Tanaka H; Kuramoto S; Takanashi K; Oikawa N
J Med Chem; 2022 Sep; 65(18):12427-12444. PubMed ID: 36066182
[TBL] [Abstract][Full Text] [Related]
7. Syntheses and evaluation of carbon-11- and fluorine-18-radiolabeled pan-tropomyosin receptor kinase (Trk) inhibitors: exploration of the 4-aza-2-oxindole scaffold as Trk PET imaging agents.
Bernard-Gauthier V; Aliaga A; Aliaga A; Boudjemeline M; Hopewell R; Kostikov A; Rosa-Neto P; Thiel A; Schirrmacher R
ACS Chem Neurosci; 2015 Feb; 6(2):260-76. PubMed ID: 25350780
[TBL] [Abstract][Full Text] [Related]
8. Trk receptor tyrosine kinases: a bridge between cancer and neural development.
Nakagawara A
Cancer Lett; 2001 Aug; 169(2):107-14. PubMed ID: 11431098
[TBL] [Abstract][Full Text] [Related]
9. Activation of TRKA receptor elicits mastocytosis in mice and is involved in the development of resistance to KIT-targeted therapy.
Yang M; Pan Z; Huang K; Büsche G; Feuerhake F; Chaturvedi A; Nie D; Heuser M; Thol F; von Neuhoff N; Ganser A; Li Z
Oncotarget; 2017 Sep; 8(43):73871-73883. PubMed ID: 29088753
[TBL] [Abstract][Full Text] [Related]
10. Neurotrophins in cultured cells from periodontal tissues.
Kurihara H; Shinohara H; Yoshino H; Takeda K; Shiba H
J Periodontol; 2003 Jan; 74(1):76-84. PubMed ID: 12593600
[TBL] [Abstract][Full Text] [Related]
11. Molecular characterization of neurotrophin expression and the corresponding tropomyosin receptor kinases (trks) in epithelial and stromal cells of the human prostate.
Dalal R; Djakiew D
Mol Cell Endocrinol; 1997 Oct; 134(1):15-22. PubMed ID: 9406845
[TBL] [Abstract][Full Text] [Related]
12. Tropomyosin receptor kinase inhibitors: a patent update 2009 - 2013.
McCarthy C; Walker E
Expert Opin Ther Pat; 2014 Jul; 24(7):731-44. PubMed ID: 24809946
[TBL] [Abstract][Full Text] [Related]
13. Rational basis for Trk inhibition therapy for prostate cancer.
Weeraratna AT; Arnold JT; George DJ; DeMarzo A; Isaacs JT
Prostate; 2000 Oct; 45(2):140-8. PubMed ID: 11027413
[TBL] [Abstract][Full Text] [Related]
14. Pan-trk inhibition decreases metastasis and enhances host survival in experimental models as a result of its selective induction of apoptosis of prostate cancer cells.
Weeraratna AT; Dalrymple SL; Lamb JC; Denmeade SR; Miknyoczki S; Dionne CA; Isaacs JT
Clin Cancer Res; 2001 Aug; 7(8):2237-45. PubMed ID: 11489797
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of WO2015042088 A1 - a novel urea-based scaffold for TrkA inhibition.
Bernard-Gauthier V; Schirrmacher R
Expert Opin Ther Pat; 2016; 26(2):291-5. PubMed ID: 26561352
[TBL] [Abstract][Full Text] [Related]
16. Trk kinase inhibitors as new treatments for cancer and pain.
Wang T; Yu D; Lamb ML
Expert Opin Ther Pat; 2009 Mar; 19(3):305-19. PubMed ID: 19441906
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic-Pharmacodynamic-Efficacy Modeling of ONO-7579, a Novel Pan-Tropomyosin Receptor Kinase Inhibitor, in a Murine Xenograft Tumor Model.
Iida H; Fujikawa R; Kozaki R; Harada R; Hosokawa Y; Ogawara KI; Ohno T
J Pharmacol Exp Ther; 2020 Jun; 373(3):361-369. PubMed ID: 32217770
[TBL] [Abstract][Full Text] [Related]
18. The genome sequence of the protostome Daphnia pulex encodes respective orthologues of a neurotrophin, a Trk and a p75NTR: evolution of neurotrophin signaling components and related proteins in the bilateria.
Wilson KH
BMC Evol Biol; 2009 Oct; 9():243. PubMed ID: 19807921
[TBL] [Abstract][Full Text] [Related]
19. Discovery of Entrectinib: A New 3-Aminoindazole As a Potent Anaplastic Lymphoma Kinase (ALK), c-ros Oncogene 1 Kinase (ROS1), and Pan-Tropomyosin Receptor Kinases (Pan-TRKs) inhibitor.
Menichincheri M; Ardini E; Magnaghi P; Avanzi N; Banfi P; Bossi R; Buffa L; Canevari G; Ceriani L; Colombo M; Corti L; Donati D; Fasolini M; Felder E; Fiorelli C; Fiorentini F; Galvani A; Isacchi A; Borgia AL; Marchionni C; Nesi M; Orrenius C; Panzeri A; Pesenti E; Rusconi L; Saccardo MB; Vanotti E; Perrone E; Orsini P
J Med Chem; 2016 Apr; 59(7):3392-408. PubMed ID: 27003761
[TBL] [Abstract][Full Text] [Related]
20. Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.
Bailey JJ; Schirrmacher R; Farrell K; Bernard-Gauthier V
Expert Opin Ther Pat; 2017 Jun; 27(6):733-751. PubMed ID: 28270010
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
